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The advantages of nebulised colistimethate sodium (CMS) in the treatment of
cystic ﬁbrosis (CF) have been shown in a number of clinical trials. Its widespread
use over four decades has proven its safety and efﬁcacy. The treatment of lung
infections by inhalation of CMS offers the possibility to achieve high antibiotic
drug concentrations at the airway surface. A product offering the advantage of two
CMS dose strengths, 1MIU ColiFin® in 3ml 0.9% saline and 2MIU ColiFin®
in 4ml 0.9% saline, was aerosol characterised in-vitro after nebulisation with
an eFlow®rapid electronic nebuliser. The delivered dose was assessed by breath
simulation experiments. NGI experiments were conducted to measure the size
distribution of the aerosol. The respirable dose (RD) representing the amount of
drug in droplets <5mm was calculated.
In-vitro results for the eFlow®rapid loaded with 1 MIU of CMS dissolved in 3ml
saline indicated a delivered dose of 27.0mg after 3.8 min of nebulisation. The
observed MMAD was 4.1mm and the calculated respirable dose was 18.0mg CMS
in droplets <5mm. For 2 MIU of CMS dissolved in 4ml saline a delivered dose of
57.8mg was obtained with a nebulisation time of 6.2min. The respirable dose was
40mg (droplets <5mm). Charging the eFlow®rapid with 2 MIU CMS/4ml results
in a twofold higher respirable dose taking only about 2.5 more minutes for inhalation
compared to the lower dose strength (1MIU/3ml). Patients in need of high dose
CMS inhalation may prefer ColiFin® 2 MIU nebulised with the eFlow®rapid due
to its short nebulisation time coupled with a reliable twofold respirable dose.
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We have adapted standard compendial methodology to characterise the aerodynamic
droplet characteristics (ADC) of nebulisers by incorporating breath simulation (BS).
Using this methodology we have determined the ADC of tobramycin 75mg/ml
(Bramitob, Chiesi, Italy) for 4ml nebulised by a Pari LC® plus with a TurboBoy
compressor (PARI, GmbH) and for an I-Neb, 300ml cup (Philips Respironics, UK).
The schematic design was BS (500ml tidal volume, inhalation:exhalation ratio
of 1:2), inhalation ﬁlter (IF), cooled Next Generation Impactor (NGI, operated at
15 L/min), nebuliser (NEB), supplementary air (15 L/min) and an exhalation ﬁlter
(EF). The results are presented in the table.
Mean (SD) data (n = 10)
PARI I-NEB
NEB (mg) 202.8 (37.2) 5.5 (2.4)
TED ex NEB (mg) 119.1 (20.8) 15.5 (2.4)
IF (mg) 32.4 (12.1) 4.4 (1.4)
EF (mg) 10.3 (5.2) 0
Tubing (mg) 13.7 (8.7) 1.0 (0.6)
FPF (%) 64.9 (4.5) 53.3 (9.9)
MMAD (mg) 3.8 (0.3) 4.4 (0.2)
GSD 2.1 (0.2) 1.7 (0.1)
FPF: ﬁne particle fraction; MMAD: mass median aerodynamic diameter; GSD: geo-
metric standard deviation.
From these data the ﬁne particle dose (FPD) from I-Neb would be 8.3mg. Separate
determinations using PARI without the NGI and supplementary air proved an IF ex
neb of 26.9(0.6)mg hence a FPD of 17.5mg.
The results highlight the use of our adapted compendial methodology to enable
ADC of breath enhanced nebulisers. Comparison of the FDPs suggests that 2
separate doses of Bramitob nebulised using an I-Neb with a 300 ml cup size could
be comparable to 4ml nebulised by a the PariLC+.
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Objectives: Two aerosolized solutions of tobramycin are currently available in Europe:
BRAMITOB® (300mg/4mL) and TOBI® (300mg/5mL). Their efﬁcacy and safety
were compared in CF patients with chronic Pa infection.
Methods: In a multinational, multicentre, open-label, non-inferiority trial, 324 CF
patients aged 6 years, with chronic Pa infection and forced expiratory volume in one
second (FEV1)  40% and  80% predicted were randomized to 28-day twice daily
treatment with BRAMITOB or TOBI, followed by 28 days without treatment. The
primary endpoint was FEV1 % predicted change from baseline at day 28. Secondary
endpoints included Pa density. Safety was assessed through adverse events (AEs)
monitoring.
Results: After 28 days, there was an increase in FEV1% predicted in both groups
over baseline: 6.99% for BRAMITOB and 7.51% for TOBI. The least squares means
were 4.66 for BRAMITOB and 5.16 for TOBI [difference: −0.50; two-sided 95%CI:
(−2.58, 1.59); ANCOVA], with signiﬁcant changes within each group (p< 0.001). After
the 28-day “off” period, FEV1 % predicted decreased, but an increase over baseline
was maintained (5.47% for BRAMITOB and 5.37% for TOBI). There was a signiﬁcant
reduction of Pa density in sputum in both groups: −2.06 log10 CFU/g for BRAMITOB
(p< 0.001) and −1.90 for TOBI (p< 0.001). Similar percentages of patients in both
groups reported AEs. Cough was the most frequent drug-related AE for TOBI group
(2.4%), compared to no patients in the BRAMITOB group.
Conclusion: BRAMITOB showed similar efﬁcacy to TOBI, with signiﬁcant improve-
ment in pulmonary function and decreased Pa density in sputum. Both treatments were
safe.
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Objectives: BRAMITOB® (300mg/4mL) and TOBI® (300mg/5mL) are the two
tobramycin aerosolized solutions available in Europe. Their efﬁcacy on lung function
considering different age classes was compared in cystic ﬁbrosis (CF) patients with
chronic Pseudomonas aeruginosa (Pa) infection.
Methods: In a multinational, multicenter, open-label, controlled trial, a total of 324
CF patients aged 6 yrs, with chronic Pa infection and forced expiratory volume in
one second (FEV1) 40% and 80% predicted were randomised to 28-day twice
daily treatment with BRAMITOB or TOBI. We examined efﬁcacy on lung function in
different age classes: children 6−12 yrs, adolescents 13−17 yrs, adults 18 yrs.
Results: Among 321 patients, 103 were children, 111 were adolescents and 107 were
adults. Statistically signiﬁcant improvements in FEV1 % predicted, adjusted by age in
classes, were observed at day 28, with no differences between the two tobramycin solu-
tions. Greater beneﬁts were observed in children and adolescents. Mean improvements
for BRAMITOB: 9.2% in children (95%CI 6.0; 12.5), 7.3% in adolescents (95%CI
4.8; 9.8), 5.0% in adults (95%CI 2.8; 7.3); for TOBI: 9.2% in children (95%CI 6.6;
11.9), 9.6% in adolescents (95%CI 7.0; 12.1), 3.6% in adults (95%CI 1.2; 5.9). Similar
ﬁndings were obtained for other pulmonary function measures, i.e. forced vital capacity
(FVC) and forced expiratory ﬂow at 25−75% FVC (FEF25−75%).
Conclusion: Tobramycin aerosolized solution improved lung function in all age groups,
with greater beneﬁts reported in children and adolescents. No differences were detected
between BRAMITOB and TOBI.
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